91 Results

People

  1. Wolchok
    Wolchok
  2. Houghton
    Houghton
  3. Merghoub
    Merghoub
  4. Panageas
    Panageas
  5. Chapman
    Chapman
  6. Yuan
    Yuan
  7. Hirschhorn Cymerman
    Hirschhorn Cymerman
  8. Gregor
    Gregor
  9. Engelhorn
    Engelhorn
  10. Perales
    Perales

Groups

  1. Department of Medicine (91)
  2. GSK Faculty (91)
  3. Melanoma and Immunotherapeutics Service (91)
  4. Solid Tumor Oncology Division (91)
  5. Sloan Kettering Institute Faculty (50)
  6. Immunology Program Faculty (44)
  7. Hematologic Malignancies, Division of (29)
  8. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (26)
  9. Sloan Kettering Institute Postdocs (23)
  10. Biostatistics Service (20)
  1. "controlled study"
  2. "Jedd Wolchok"
Formats
  1. Journal Article (90)
  2. Research Letter (1)
Groups
  1. Department of Medicine (91)
  2. GSK Faculty (91)
  3. Melanoma and Immunotherapeutics Service (91)
  4. Solid Tumor Oncology Division (91)
  5. Sloan Kettering Institute Faculty (50)
  6. Immunology Program Faculty (44)

More Groups

People
  1. Jedd Wolchok (91)
  2. Alan Houghton (42)
  3. Taha Merghoub (23)
  4. Katherine Panageas (17)
  5. Paul Chapman (17)
  6. Jianda Yuan (15)

More People

Years
  1. 2021 (1)
  2. 2020 (5)
  3. 2019 (1)
  4. 2018 (4)
  5. 2017 (4)
  6. 2015 (6)

More Years

Publications
  1. Clinical Cancer Research (10)
  2. Journal of Clinical Oncology (6)
  3. Vaccine (6)
  4. PLoS ONE (5)
  5. Journal of Experimental Medicine (4)
  6. Lancet Oncology (4)

More Publications

Publishers
  1. American Association for Cancer Research (14)
  2. Nature Publishing Group (12)
  3. Elsevier Inc. (9)
  4. American Society of Clinical Oncology (6)
  5. Elsevier Science, Inc. (5)
  6. Public Library of Science (5)

More Publishers

Results (91)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: A two-center observational study
    Journal Article

    Zou, F.; Faleck, D.; Thomas, A.; Harris, J.; Satish, D.; Wang, X.; Charabaty, A.; Ernstoff, M. S.; Glitza Oliva, I. C.; Hanauer, S.; more...
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Determinants of COVID-19 disease severity in patients with cancer
    Research Letter

    Robilotti, E. V.; Babady, N. E.; Mead, P. A.; Rolling, T.; Perez-Johnston, R.; Bernardes, M.; Bogler, Y.; Caldararo, M.; Figueroa, C. J.; Glickman, M. S.; more...
    Nature Medicine (2020)

    Fulltext@MSK | Save
  • Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring
    Journal Article

    Zviran, A.; Schulman, R. C.; Shah, M.; Hill, S. T. K.; Deochand, S.; Khamnei, C. C.; Maloney, D.; Patel, K.; Liao, W.; Widman, A. J.; more...
    Nature Medicine (2020)

    Fulltext@MSK | Save
  • CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors
    Journal Article

    Wang, H.; Franco, F.; Tsui, Y. C.; Xie, X.; Trefny, M. P.; Zappasodi, R.; Mohmood, S. R.; Fernández-García, J.; Tsai, C. H.; Schulze, I.; more...
    Nature Immunology (2020)

    Fulltext@MSK | Save
  • ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity
    Journal Article

    Moral, J. A.; Leung, J.; Rojas, L. A.; Ruan, J.; Zhao, J.; Sethna, Z.; Ramnarain, A.; Gasmi, B.; Gururajan, M.; Redmond, D.; more...
    Nature (2020)

    Fulltext@MSK | Save
  • Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
    Journal Article

    Mamoor, M.; Postow, M. A.; Lavery, J. A.; Baxi, S. S.; Khan, N.; Mao, J. J.; Rogak, L. J.; Sidlow, R.; Thom, B.; Wolchok, J. A.; more...
    Journal for ImmunoTherapy of Cancer (2020)

    Fulltext@MSK | Save
  • In situ vaccination with defined factors overcomes T cell exhaustion in distant tumors
    Journal Article

    Khalil, D. N.; Suek, N.; Campesato, L. F.; Budhu, S.; Redmond, D.; Samstein, R. M.; Krishna, C.; Panageas, K. S.; Capanu, M.; Houghton, S.; more...
    Journal of Clinical Investigation (2019)

    Fulltext@MSK | Save
  • Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial
    Journal Article

    Hodi, F. S.; Chiarion-Sileni, V.; Gonzalez, R.; Grob, J. J.; Rutkowski, P.; Cowey, C. L.; Lao, C. D.; Schadendorf, D.; Wagstaff, J.; Dummer, R.; more...
    Lancet Oncology (2018)

    Fulltext@MSK | Save
  • Non-conventional inhibitory CD4(+)Foxp3(−)PD-1(hi) T cells as a biomarker of immune checkpoint blockade activity
    Journal Article

    Zappasodi, R.; Budhu, S.; Hellmann, M. D.; Postow, M. A.; Senbabaoglu, Y.; Manne, S.; Gasmi, B.; Liu, C.; Zhong, H.; Li, Y.; more...
    Cancer Cell (2018)

    Fulltext@MSK | Save
  • Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma
    Journal Article

    Shoushtari, A. N.; Friedman, C. F.; Navid-Azarbaijani, P.; Postow, M. A.; Callahan, M. K.; Momtaz, P.; Panageas, K. S.; Wolchok, J. D.; Chapman, P. B.
    JAMA Oncology (2018)

    Fulltext@MSK | Save